SPRO vs. BNTC

Last updated Apr 1, 2026

Compare and contrast key facts about Spero Therapeutics, Inc. (SPRO) and Benitec Biopharma Inc. (BNTC).

Performance

SPRO vs. BNTC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Spero Therapeutics, Inc. (SPRO) and Benitec Biopharma Inc. (BNTC). The values are adjusted to include any dividend payments, if applicable.

SPRO vs. BNTC - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
SPRO Spero Therapeutics, Inc.	0.43%	126.21%	-29.93%	-15.03%	-89.19%	-17.43%	101.66%	56.34%	-47.66%	2.17%
BNTC Benitec Biopharma Inc.	-20.94%	6.65%	291.02%	11.76%	-93.51%	-12.67%	-60.78%	-66.00%	-49.27%	5.71%

Fundamentals

EPS SPRO : -$0.78 BNTC : -$1.23
PS Ratio SPRO : 3.67 BNTC : 789.82
Total Revenue (TTM) SPRO : $35.77M BNTC : $556.00K
Gross Profit (TTM) SPRO : -$72.47M BNTC : -$6.52K
EBITDA (TTM) SPRO : -$45.15M BNTC : -$55.03M

Returns By Period

In the year-to-date period, SPRO achieves a 0.43% return, which is significantly higher than BNTC's -20.94% return.

SPRO

• 1D: 4.46%
• 1M: 7.83%
• YTD: 0.43%
• 6M: 24.47%
• 1Y: 225.00%
• 3Y*: 17.30%
• 5Y*: -30.35%
• 10Y*: —

BNTC

• 1D: 5.86%
• 1M: -2.29%
• YTD: -20.94%
• 6M: -24.09%
• 1Y: -18.14%
• 3Y*: 43.98%
• 5Y*: -35.95%
• 10Y*: -31.08%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

SPRO vs. BNTC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SPRO

SPRO Risk / Return Rank: 90
SPRO Sharpe Ratio Rank: 72
SPRO Sortino Ratio Rank: 99
SPRO Omega Ratio Rank: 98
SPRO Calmar Ratio Rank: 94
SPRO Martin Ratio Rank: 87

BNTC

BNTC Risk / Return Rank: 27
BNTC Sharpe Ratio Rank: 28
BNTC Sortino Ratio Rank: 30
BNTC Omega Ratio Rank: 30
BNTC Calmar Ratio Rank: 24
BNTC Martin Ratio Rank: 25

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SPRO vs. BNTC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Spero Therapeutics, Inc. (SPRO) and Benitec Biopharma Inc. (BNTC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SPRO	BNTC	Difference
Sharpe ratio Return per unit of total volatility	0.90	-0.29	+1.19
Sortino ratio Return per unit of downside risk	6.29	0.00	+6.29
Omega ratio Gain probability vs. loss probability	1.78	1.00	+0.78
Calmar ratio Return relative to maximum drawdown	5.16	-0.53	+5.68
Martin ratio Return relative to average drawdown	9.02	-0.95	+9.96
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SPRO vs. BNTC - Sharpe Ratio Comparison

The current SPRO Sharpe Ratio is 0.90, which is higher than the BNTC Sharpe Ratio of -0.29. The chart below compares the historical Sharpe Ratios of SPRO and BNTC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	SPRO	BNTC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.90	-0.29	+1.19
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.20	-0.35	+0.15
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.24	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.14	-0.30	+0.16

Correlation

The correlation between SPRO and BNTC is 0.12, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

SPRO vs. BNTC - Dividend Comparison

Neither SPRO nor BNTC has paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018
SPRO Spero Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
BNTC Benitec Biopharma Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.20%

Drawdowns

SPRO vs. BNTC - Drawdown Comparison

The maximum SPRO drawdown since its inception was -97.46%, roughly equal to the maximum BNTC drawdown of -99.91%. Use the drawdown chart below to compare losses from any high point for SPRO and BNTC.

Drawdown Indicators

	SPRO	BNTC	Difference
Max Drawdown Largest peak-to-trough decline	-97.46%	-99.91%	+2.45%
Max Drawdown (1Y) Largest decline over 1 year	-39.80%	-39.25%	-0.55%
Max Drawdown (5Y) Largest decline over 5 years	-97.13%	-98.05%	+0.92%
Max Drawdown (10Y) Largest decline over 10 years	—	-99.82%	—
Current Drawdown Current decline from peak	-89.40%	-99.50%	+10.10%
Average Drawdown Average peak-to-trough decline	-61.75%	-87.36%	+25.61%
Ulcer Index Depth and duration of drawdowns from previous peaks	22.77%	21.83%	+0.94%

Volatility

SPRO vs. BNTC - Volatility Comparison

The current volatility for Spero Therapeutics, Inc. (SPRO) is 13.13%, while Benitec Biopharma Inc. (BNTC) has a volatility of 18.47%. This indicates that SPRO experiences smaller price fluctuations and is considered to be less risky than BNTC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SPRO	BNTC	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.13%	18.47%	-5.34%
Volatility (6M) Calculated over the trailing 6-month period	32.66%	48.10%	-15.44%
Volatility (1Y) Calculated over the trailing 1-year period	252.14%	62.64%	+189.50%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	151.63%	102.83%	+48.80%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	125.84%	132.20%	-6.36%

Financials